NAS:HZNP (Ireland) Also Trade In: Brazil Germany Mexico

Horizon Therapeutics PLC $ 76.06 1.79 (2.41%)

On watch
Volume:
1,983,715
Avg Vol (1m):
2,049,644
Market Cap $:
16.76 Bil
Enterprise Value $:
17.20 Bil
P/E (TTM):
31.18
P/B:
6.42
Warning! GuruFocus has detected 1 Severe warning sign with HZNP. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)

HZNP News and Headlines - Horizon Therapeutics PLC

GuruFocus Articles Total 11
  • 1

Discussion of markets and holdings

To Our Shareholders:

CGM Mutual Fund increased 20.7% during the second quarter of 2020 compared to a return of 20.5% for the Standard and Poor's 500 Index (S&P 500 Index) and 2.9% for the ICE BofAML U.S. Corporate, Government and Mortgage Index*. For the first six months of the year, CGM Mutual Fund decreased -12.9%, the S&P 500 Index decreased -3.1% and the ICE BofAML U.S. Corporate, Government and Mortgage Index returned 6.3%.

In the wake of a stormy late February and March, the market experienced a surprisingly strong rebound in the second quarter of 2020. The rally was not

37 Views    Sydnee Gatewood    2020-08-20 19:57
Horizon Therapeutics PLC tops the list

Growth focused investors may be interested in the following stocks, as their price-earnings ratios are below 20 and their earnings per share have grown significantly over the past year.

Horizon Therapeutics PLC

The first company that meets the above listed criteria is Horizon Therapeutics PLC (HZNP), an Irish biotech developer of treatments for patients affected by rare and rheumatic diseases.

The company’s trailing 12-month EPS increased to $3.02 as of the first quarter of 2020, up from 48 cents in the same quarter of 2019.

The price-earnings ratio is 18.57 (versus the industry median of 22.92) as of June 22.

149 Views    Alberto Abaterusso    2020-06-23 14:38
Horizon's drug for thyroid eye disease could replace invasive surgery for many and bring in $750 million annually

If faced with the choice between invasive surgery versus a few shots, most would probably choose the latter, ophthalmologists included. Patients with bulging eyes from thyroid eye disease may finally have a long-term solution for their eye predicament in new injections specifically designed to alleviate the cause of the disease. And it looks as though the company behind it, Horizon Pharma (HZNP), may end up having the whole market to itself for a while.

It’s not a particularly huge market, but with 12 years of exclusivity ahead, nearly flawless efficacy and safety results showing fast action and no close competitors

36 Views    Matt Winkler    2019-04-29 16:36
Company raised full-year guidance

Shares of Horizon Pharma PLC (HZNP) gained in Monday trading after the company reported financial results for its third quarter. EPS of 26 cents beat analysts' expectations by four cents and revenue of $271.6 million beat estimates by $11.86 million but declined 0.8% year over year.

“Our third-quarter results reflect our dedicated focus on execution, driven by 65 percent year-over-year growth of our diverse portfolio of rare disease medicines,” Chairman, President and CEO Timothy P. Walbert said.Â

Further, the gross profit margin reached 53.8%, down from 59.2% in the prior-year quarter. The non-GAAP gross profit margin was 89.6%, which

76 Views    Omar Venerio    2017-11-06 22:48
The hedge fund guru's largest 3rd-quarter sales

Julian Robertson (Trades, Portfolio) is considered the father of the hedge fund. He launched his firm Tiger Management in 1980 with $8 million and turned it into over $22 billion in the late 1990s. During the third quarter the guru’s largest sells were the following:

He reduced his stake in Delta Air Lines Inc. (DAL) by 82.11% with an impact of -5.58% on the portfolio.

The company provides scheduled air transportation for passengers and cargo throughout the U.S. and around the world. The company's business segments are airline and refinery. Third-quarter operating revenue decreased 5.6% with

416 Views    Tiziano Frateschi    2016-12-07 19:28
Guru's investments include Teva Pharmaceutical, Dollar Tree

Julian Robertson (Trades, Portfolio) of Tiger Management made eight new buys in a wide range of sectors in the fourth quarter. His preferred sectors, Technology and Healthcare, were well represented.

Robertson’s most significant new buy in the fourth quarter was his investment in Teva Pharmaceutical Industries Ltd. (TEVA), an Israeli pharmaceutical company. Robertson purchased a 595,300-share stake for an average price of $61.94 per share. The deal had a 5.04% impact on Robertson’s portfolio.

The stake is 0.07% of Teva’s outstanding shares and 5.04% of Robertson’s total assets. Andreas Halvorsen (Trades, Portfolio) is Teva’s

1070 Views    David Goodloe    2016-03-09 19:09
Hedge fund adds 19 new stocks to portfolio

Sheets Smith Wealth Management is a hedge fund based in North Carolina that, on its last quarterly 13F, reported a total value of its portfolio of $365 million, with an increase of 1.02% since the previous quarter. During Q2 2015 the investment professional bought 19 new stocks and increased 84 of its existing stakes. The following are the most heavily weighted buys during the quarter.

It bought shares of Allergan PLC (AGN) with an impact of 2.48% on its portfolio. The Investor, as well as other hedge funds such as Moody Lynn & Lieberson,

1685 Views    Tiziano Frateschi    2015-09-01 19:06

Horizon Pharma (HZNP) is currently reporting triple-digit year-to-date and one-year stock returns. As of Aug. 24, the company has a year-to-date stock return of 124.98% and a one-year stock return of 198.97%.

Recently the company has received a great deal of press for its acquisition attempt of Depomed (DEPO). In July, Depomed rejected Horizon Pharma’s most recent offer for a takeover which valued the company at $33 per share. Depomed has been unwilling to enter into negotiations for a merger of the two companies, and in July amongst various negotiation attempts also enacted a poison pill plan which blocks any

1011 Views    Julie Young    2015-08-24 22:29

Steven Mandel’s hedge fund, Lone Pine Capital, on July 27 initiated a position in Horizon Pharma Plc (HZNP), according to GuruFocus Real Time Picks.

The purchase was for 8,353,668 shares, which represent 5.4% of the drug company.

Horizon Pharma, which has acquired four other companies in the past two years, is in the process of attempting to merge with Depomed Inc. (DEPO), a maker of neurology treatments. The July 7 proposal offered $29.25 per share for Depomed, a 42% premium to its closing share price the previous day. Horizon raised its offer price to $33 on

1763 Views    Holly LaFon    2015-07-28 05:14

Wall Street climbed more than 1% on last Monday, carrying the upward momentum to the closing bell. Stock market rebounded from a sharp decline last week, helped by the deal making in healthcare sector and surge in energy shares. On March 30, Dow Jones industrial average gained 263.65 points, or by 1.5%, to 17,976.31, its biggest daily percentage gain since Feb 3. The S&P 500 index added 25.22 points, or rose by 1.22% to 2,086.24. The Nasdaq composite rose 56.22 points, or 1.15%, to 4,947.44.

The stocks in European markets followed the trend in the U.S. markets and also rallied.

728 Views    Business Reports    2015-04-06 14:52

https://s3.amazonaws.com/gurufocus_userupload/03May20171139241493829564.jpg

Horizon Pharma (HZNP) said that pre-clinical data from an investigator initiated study demonstrated that treatment with murine interferon gamma, which is an analogue of interferon gamma-1b (ACTIMMUNE(R)), improved the signs of disease severity in a mouse model of Autosomal Dominant Osteopetrosis Type II, the most common form of osteopetrosis, a group of conditions characterized by an increased skeletal mass due to impaired bone and cartilage resorption.

HZNP's ACTIMMUNE, a biologically manufactured protein similar to one the body makes naturally to help prevent infection, is currently FDA-approved for use in two rare diseases. It is indicated to

826 Views    riddock57    2015-03-09 18:23

Headlines Total 148
  • 1
  • 2

2020-10-22 $ 76.06 (2.41%)
2:38pm
2020-10-15 $ 79.33 (-1.22%)
10:30am
9:11am
2020-10-13 $ 80.11 (-1.54%)
11:10am
10:09am
2020-10-12 $ 81.36 (-3.59%)
8:25am
2020-10-06 $ 80.1 (-1.79%)
6:42pm
2020-10-05 $ 81.56 (2.18%)
12:24pm
10:59am
10:04am
10:00am
2020-10-01 $ 80.42 (3.53%)
12:54pm
8:04am
2020-09-29 $ 78.16 (-1.9%)
9:48am
6:42am
2020-09-28 $ 79.67 (1.81%)
11:38am
11:35am
2020-09-25 $ 78.25 (3.88%)
4:09pm
8:30am
6:53am
2020-09-24 $ 75.33 (-5.58%)
12:29pm
9:22am
2020-09-23 $ 79.78 (2.07%)
11:54am
10:40am
2020-09-22 $ 78.16 (-0.86%)
11:19am
2020-09-18 $ 79.93 (2.53%)
4:15pm
12:17pm
10:30am
2020-09-15 $ 78.97 (3.09%)
9:13am
2020-09-10 $ 70.79 (-2.37%)
7:36am
2020-09-09 $ 72.51 (4.03%)
11:44am
11:42am
10:14am
2020-09-04 $ 71.53 (-0.93%)
11:12am
11:08am
10:31am
9:45am
2020-09-03 $ 72.2 (-4.22%)
8:34am
2020-09-02 $ 75.38 (-0.12%)
12:24pm
9:49am
9:33am
8:25am
2020-09-01 $ 75.47 (0.47%)
10:31am
9:10am
2020-08-27 $ 73.33 (0.36%)
9:17am
2020-08-26 $ 73.07 (-0.88%)
12:01pm
8:09am
7:24am
2020-08-25 $ 73.72 (0.59%)
5:15pm
12:25pm
10:54am
9:52am
2020-08-24 $ 73.29 (-2.73%)
11:26am
8:56am
8:43am
6:55am
2020-08-21 $ 75.35 (0.31%)
11:56am
8:30am
5:30am
2020-08-20 $ 75.12 (1.16%)
8:46am
8:42am
2020-08-19 $ 74.26 (1.49%)
9:17am
7:46am
2020-08-18 $ 73.17 (-1.96%)
4:04pm
8:21am
2020-08-17 $ 74.63 (2.49%)
8:22am
2020-08-14 $ 72.82 (0.57%)
12:53pm
10:57am
8:18am
2020-08-13 $ 72.41 (-0.33%)
11:48am
10:19am
2020-08-11 $ 71.67 (-5.5%)
12:05pm
10:26am
10:10am
8:44am
7:48am
2020-08-10 $ 75.84 (-0.29%)
10:55am
10:22am
6:50am
2020-08-07 $ 76.06 (5.32%)
12:22pm
10:44am
2020-08-06 $ 72.22 (-5.45%)
12:19pm
10:37am
10:19am
9:54am
9:23am
9:05am
2020-08-05 $ 76.38 (23.61%)
12:26pm
11:10am
10:57am
10:42am
7:55am
2020-08-04 $ 61.79 (-2.03%)
11:16am
2020-08-03 $ 63.07 (3.07%)
10:40am
2020-07-29 $ 60.39 (1.87%)
11:33am
2020-07-24 $ 58.47 (-0.49%)
11:10am
2020-07-17 $ 57.88 (1.44%)
8:52am
2020-07-14 $ 56.17 (0.57%)
6:38pm
9:49am
2020-07-08 $ 58.76 (2.57%)
7:07am
Total 148
  • 1
  • 2